(Q53200395)

12 May 2018

title

HER2 status in primary stage T1 urothelial cell carcinoma of the urinary bladder. (English)

1 reference

12 May 2018

author name string

Hans Olsson

1

1 reference

12 May 2018

Ing-Marie Fyhr

2

1 reference

12 May 2018

Per Hultman

3

1 reference

12 May 2018

Staffan Jahnson

4

1 reference

12 May 2018

publication date

12 December 2011

1 reference

12 May 2018

Scandinavian Journal of Urology and Nephrology

published in

1 reference

12 May 2018

volume

46

1 reference

12 May 2018

page(s)

102-107

1 reference

12 May 2018

issue

2

1 reference

12 May 2018

American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer

cites work

1 reference

https://api.crossref.org/works/10.3109%2F00365599.2011.637955

Her-2/neu testing and therapy in gastroesophageal adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365599.2011.637955

HER2 testing in gastric cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365599.2011.637955

Recent advances in cancer therapy: an overview.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365599.2011.637955

Personalized medicine: individualized care of cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365599.2011.637955

The World Health Organization/International Society of Urological Pathology consensus classification of urothelial (transitional cell) neoplasms of the urinary bladder. Bladder Consensus Conference Committee

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365599.2011.637955

Multivariate analysis of the prognostic factors of primary superficial bladder cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365599.2011.637955

Molecular pathways of urothelial development and bladder tumorigenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365599.2011.637955

Combined gene expression and genomic profiling define two intrinsic molecular subtypes of urothelial carcinoma and gene signatures for molecular grading and outcome.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365599.2011.637955

Assessing HER2 gene amplification as a potential target for therapy in invasive urothelial bladder cancer with a standardized methodology: results in 1005 patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365599.2011.637955

No strong association between HER-2/neu protein overexpression and gene amplification in high-grade invasive urothelial carcinomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365599.2011.637955

Role of polysomy 17 in transitional cell carcinoma of the bladder: immunohistochemical study of HER2/neu expression and fish analysis of c-erbB-2 gene and chromosome 17.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365599.2011.637955

Does HER2/neu expression provide prognostic information in patients with advanced urothelial carcinoma?

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365599.2011.637955

Changes of HER2 status in circulating tumor cells compared with the primary tumor during treatment for advanced breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365599.2011.637955

Assessment of methods for tissue-based detection of the HER-2/neu alteration in human breast cancer: a direct comparison of fluorescence in situ hybridization and immunohistochemistry

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365599.2011.637955

Testing HER2 in breast cancer: a comparative study on BRISH, FISH, and IHC.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365599.2011.637955

Role of anti-Her-2 therapy in bladder carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00365599.2011.637955

10.3109/00365599.2011.637955

21 January 2018

Identifiers

DOI

1 reference

12 May 2018

PubMed ID

22150625

1 reference

12 May 2018